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Abstract 
Stathmin 1 (STMN1) is a microtubule destabilizer 
protein with an important role in cell cycle 
progression, cell proliferation, migration and 
survival. The present review on STMN1 contains 
data on DNA/RNA, on the protein encoded and 
where the gene is implicated. 
Identity 
Other names: C1orf215, LAP18, Lag, OP18, 
PP17, PP19, PR22, SMN 
HGNC (Hugo): STMN1 
Location: 1p36.11 
DNA/RNA 
Note 
The entire STMN1 gene is about 22.8 kb and 
contains 5 exons (start: 26210672 bp and end: 
26233482; orientation: minus strand).  
The STMN1 gene encodes 2 isoforms, A and B. 
Isoform A contains 3 transcript variants that differ 
in the 5' UTR and have an alternate terminal exon, 
compared to isoform B, resulting in a shorter and 
distinct C-terminus. The isoform B represents the 
longest transcript variant. 
Protein 
Description 
Stathmin 1 belongs to the Stathmin protein family, 
which is characterized by the presence of a 
Stathmin-like domain (also known as tubulin-
binding domain) that participates in 
interactions/sequestering of alpha/beta-tubulin 
heterodimers (Figure 1). 
Expression 
Ubiquitous. Stathmin 1 is highly expressed during 
embryonic development. In adult cells, it is 
expressed during cell proliferation, and in nervous 
tissue and testis (revised in Curmi et al., 1999). 
 
 
Figure 1. Representation of primary structure of Stathmin 1 protein. The catastrophe promotion region (aa 1 - 99) and the 
four serine phosphorylation sites (S16, S25, S38 and S63) at the N-terminal, and the tubulin binding domain (aa 25 - 149) at the 
C-terminal are illustrated in the figure. Reproduced with permission of the editor-in-chief of BMB reports from Machado-Neto et 
al., 2014b. 
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Figure 2. Intracellular localization of Stathmin 1 protein in HeLa cells. Confocal analysis of HeLa cells displaying Stathmin 1 
(green), Actin (red) and DAPI (blue) staining; MERGE shows the overlapped images. Scale bar: 10 µm. Note the predominant 
cytoplasmic localization of Stathmin 1. Anti-Stathmin 1 (OP18; sc-55531) was from Santa Cruz Biotechnology, (Santa Cruz, CA, 
USA), Phalloidin (A12379) and DAPI (P-36931) were from Invitrogen (Carlsbad, CA, USA). Personal data. 
 
 
Localisation 
Stathmin 1 is predominantly found in the cytoplasm 
(Figure 2). 
Function 
Stathmin 1 is a phosphoprotein that participates in 
microtubule catastrophe and/or in the sequestering 
of alpha/beta-tubulin heterodimers, regulates 
microtubule dynamics, cell cycle progression, 
proliferation, motility and survival (Curmi et al., 
1999; Belletti and Baldassarre, 2011). The main 
mechanism of regulation of Stathmin 1 activity on 
based in its phophorylated and unphosphorylated 
status at serine sites (residues 16, 25, 38 and 68). 
Stathmin 1 phosphorylation at serine 16 and/or 63 
reduces the affinity between Stathmin 1 and 
alpha/beta-tubulin heterodimers. The proteins that 
are able to phosphorylate Stathmin 1 at serine 16 
and/or 63 are: aurora kinase B, protein kinase A 
(PKA), P21 protein (Cdc42/Rac)-activated kinase  
(PAK1) and Ca2+/calmodulin-dependent protein 
kinases (CamKs). Serine 25 and/or 38 may be 
phosphorylated by cyclin-dependent kinases 
(CDKs), mitogen-activated protein kinases 
(MAPKs) and phosphoinositide 3-kinase (PI3K) 
(Belletti and Baldassarre, 2011).  
Phosphatase proteins that are able to 
dephosphorylate Stathmin 1 includes: protein 
phosphatase 1 (PP1), protein phosphatase 2A 
(PP2A) and protein phosphatase 2B (PP2B) (Guy et 
al., 1992; Tournebize et al., 1997; Mistry et al., 
1998) (Figure 3). 
Homology 
Stathmin 1 shares high homology with the other 
members of the Stathmin protein family including 
Stathmin-like 2 (also named SCG10), Stathmin-like 
3 (also named SCLIP) and Stathmin-like 4 (also 
named RB3). Stathmin 1 also shares high homology 
among different species (Table 1). 
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Figure 3. Stathmin 1 signaling. Stathmin 1 may be phosphorylated on serine sites by cyclin-dependent kinases (CDKs), 
mitogen-activated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K), aurora kinase B (AURKB), protein kinase A 
(PKA), and Ca2+/calmodulin-dependent protein kinases (CamKs), leading to microtubule stability. On the other hand, Stathmin 1 
may be dephosphorylated by protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A) and protein phosphatase 2B (PP2B), 
resulting in microtubule instability. Abbreviations: TKR: tyrosine kinase receptor; P: phosphorylation; Ac: acetylation. This figure 
was performed using Servier Medical Art tools (http://www.servier.com/Powerpoint-image-bank). 
 
Mutations 
Recurrent mutations in the STMN1 gene are rare, 
10 missense, 8 nonsense, 1 nonstop extension and 3 
coding silent mutations are reported at COSMIC 
(catalogue of somatic mutations in cancer; 
COSMIC). In human esophageal adenocarcinoma,  
STMN1 Q18E mutation was identified and 
presented transformation potential in vitro and in 
vivo in NIH3T3 cells (Misek et al., 2002).  
Studies performed in leukemia cells indicate that 
the Q18E mutation results in Stathmin 1 
hyperactivity and contributes to chromosomal 
instability (Holmfeldt et al., 2006). 
Implicated in 
Various cancers 
Note 
The role and clinical impact of Stathmin 1 has been 
extensively addressed in many types of human 
cancers. In general, the increased expression of 
Stathmin 1 is found in many cancers and confers a 
poor prognosis (revised in Belletti and Baldassarre, 
2011 and Rana et al., 2008). Using cancer cell line  
models, several groups have demonstrated that 
Stathmin 1 inhibition may partially reverse the 
malignant phenotype. 
Hematopoietic neoplasms 
Note 
Stathmin 1 was initially identified by proteomics 
analysis of HL60 leukemia cells (Feuerstein and 
Cooper, 1983). In primary acute leukemia and 
lymphoma samples, and leukemia cell lines, several 
independent groups have showed that Stathmin 1 is 
highly expressed (Hanash et al., 1988; Melhem et 
al., 1991; Melhem et al., 1997; Roos et al., 1993; 
Machado-Neto et al., 2014a; Brattsand et al., 1993); 
however its impact on survival outcome remains 
unknown. A recent study of immunophenotypic and 
molecular features of a large series of follicular 
lymphomas indicated that Stathmin 1 represents an 
useful novel diagnostic marker for these diseases 
(Marafioti et al., 2013). Importantly, Stathmin 1 
silencing resulted in marked inhibition of 
tumorigenicity, proliferation and clonogenicity in 
leukemia cell lines (K562, U937 and Namalwa 
cells) (Machado-Neto et al., 2014a; Jeha et al., 
1996; Iancu et al., 2001). 
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Table 1. Comparative identity of human STMN1 with other species. Source: HomoloGene. 
 
 
In a study that focused on the identification of 
biomarkers of human aging and aging-related 
diseases, Stathmin 1 was found upregulated in 
plasma samples from myelodysplastic patients 
(Jiang et al., 2008). Recently, increased levels of 
Stathmin 1 were reported in bone marrow and 
CD34+ cells from high-risk myelodysplastic 
syndromes patients and during disease progression 
(Machado-Neto et al., 2014a). Notably, higher 
Stathmin 1 expression was associated with high-
risk disease and higher bone marrow blasts 
percentage (Machado-Neto et al., 2014a), but did 
not impacted survival.  
Stathmin 1 was also identified as one of the 15 most 
relevant genes for determining the outcome in 
myeloma multiple patients by microarray approach 
(Decaux et al., 2008). 
Breast cancer 
Note 
Using Western blot analysis, Brattsand (Brattsand, 
2000) reported that Stathmin 1 expression 
positively correlated with proliferation status and 
aggressiveness in a panel of 151 primary breast 
carcinoma samples. Similar results were found by 
Curmi and colleagues (Curmi et al., 2000), who 
also reported that Stathmin 1 overexpression 
correlated with loss of steroid receptors, 
histopathological grade III and mitotic index. 
Importantly, Stathmin 1 expression was indicated 
as a potential tool for predicting the outcome of 
breast cancer patients with lymph node metastasis 
and its expression was increased in the group with 
poor prognosis (Oishi et al., 2007). By multivariate 
analysis, high Stathmin 1 expression predicted 
reduced disease-free survival (Saal et al., 2007; 
Golouh et al., 2008; Baquero et al., 2012) and 
overall survival (Baquero et al., 2012). Decreased 
Stathmin 1 phosphorylation at serine 16 (an 
inhibitory site) correlated with the more metastatic 
phenotype in breast cancers cell lines and primary 
tumors (Li et al., 2011). Using breast cancer cell 
lines and gene therapy tools, Stathmin 1 inhibition, 
by adenovirus-mediated gene transfer of anti-
Stathmin 1 ribozyme, resulted in a dose-dependent 
inhibition of proliferation, apoptosis induction and 
had an additive effect together low concentration of 
taxol treatment in vitro and in vivo (Miceli et al., 
2013). 
Ovarian cancer 
Note 
Stathmin 1 overexpression has been described in 
ovarian cancer patients (Alaiya et al., 1997; Price et 
al., 2000). Wei and colleagues (Wei et al., 2008) 
observed that Stathmin 1 was expressed in all 
ovarian cancer samples analyzed and higher levels 
were observed in the metastatic tumors and 
negatively impacted survival by univariate analysis. 
In agreement, Stathmin 1 overexpression was found 
in primary high-grade serous ovarian carcinomas 
and ovarian cancer cell lines (Karst et al., 2011). 
High levels of Stathmin 1 predicted an unfavorable 
prognosis in ovarian cancer patients under 
paclitaxel and/or platinum therapy (Su et al., 2009; 
Aoki et al., 2009) also by univariate analysis. In 
p53 mutated ovarian cancer cell lines, Stathmin 1 
silencing caused cell cycle arrest and apoptosis in 
vivo and in vivo (Sonego et al., 2013). 
Head and neck cancer 
Note 
Using proteomics approach, Stathmin 1 was found 
to be differently expressed in oral squamous-cell 
carcinoma and laryngeal squamous-cell carcinoma 
(Koike et al., 2005; Sewell et al., 2007). Stathmin 1 
expression was also found to be significantly 
increased in oral squamous-cell carcinoma cell lines 
and primary tumors and its high expression 
correlated with advanced stages of the disease and 
poor disease-free survival by univariate analysis 
(Kouzu et al., 2006). In head-neck squamous-cell 
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carcinoma, Stathmin 1 was expressed at low levels 
(76% cases) and did not impact recurrence 
(Canzonieri et al., 2012). Cheng and colleagues 
(Cheng et al., 2008) identified an upregulation of 
Stathmin 1 in primary nasopharyngeal carcinoma 
and its expression was associated with recurrence 
and advanced stages of the disease. In agreement, 
Hsu and colleagues (Hsu et al., 2014) reported that 
Stathmin 1 was overexpressed in approximately 
50% of the nasopharyngeal carcinoma samples and 
was associated with advanced age, high-grade 
tumors and was an independent predictor of worse 
disease-free survival. Notably, knockdown of 
Stathmin 1 suppressed cell cycle progression, 
proliferation, migration, invasion, xenograft tumor 
growth, induced apoptosis and potentiated 
paclitaxel response in nasopharyngeal carcinoma 
cell lines (CNE1-LMP1 and HNE2 cells) (Wu et 
al., 2014). 
Hepatocarcinoma 
Note 
Yuan and colleagues (Yuan et al., 2006) reported a 
high Stathmin 1 expression in 56% of 156 
hepatocarcinoma patients and high Stathmin 1 
expression was associated with increased tumor 
size, tumor grade, metastasis, p53 mutation status 
and negatively impacted survival in univariate 
analysis. In agreement, elevated Stathmin 1 levels 
were also reported by Singer and colleagues (Singer 
et al., 2007) and were associated with the presence 
of undifferentiated tumors. Other studies observed 
an increased Stathmin 1 expression in tumor tissue 
compared to matched normal tissue, and a positive 
association between Stathmin 1 overexpression and 
recurrence or poor prognosis in univariate analysis 
(Hsieh et al., 2010; Chen et al., 2013b). In 
hepatocarcinoma cell lines, Stathmin 1 silencing 
reduced cell proliferation, viability, migration and 
augmented the response to paclitaxel, vinblastine 
and cisplatin treatment (Singer et al., 2007; Hsieh et 
al., 2010; Gan et al., 2010). 
Endometrial cancer 
Note 
In a multicenter study including 1076 endometrial 
patients, Stathmin 1 overexpression was detected in 
37% of cases and correlated with high grade disease 
and aneuploidy, and was an independent predictor 
of metastasis and worse disease specific survival 
(Trovik et al., 2011). In another study from the 
same group (Trovik et al., 2010), high Stathmin 1 
expression was associated with a higher probability 
of endometrial cancer recurrence and PI3K 
activation. Additionally, a study conducted by 
Salvesen and colleagues (Salvesen et al., 2009), 
investigating the impact of PI3K activation in 
endometrial cancer, identified that high Stathmin 1 
expression was an independent predictor of 
aggressive phenotype and worse survival. Of note, 
Wik and colleagues (Wik et al., 2013) reported that 
the levels of Stathmin 1 phosphorylation at serine 
38 site were associated with poor prognosis, tumor 
cell proliferation, increased PIK3CA copy number 
and PI3K activation by multivariate analysis. 
Werner and colleagues (Werner et al., 2014), using 
endometrial cancer cell lines, showed that Stathmin 
1 silencing potentiated the response to paclitaxel 
treatment. This finding was confirmed in vivo: 
endometrial cancer patients with high Stathmin 1 
expression had a poor response to paclitaxel therapy 
(Werner et al., 2014). 
Bladder cancer and urothelial 
carcinoma 
Note 
Using quantitative PCR targeting 110 relevant 
cancer genes, Dubosq and colleagues (Dubosq et 
al., 2012) detected Stathmin 1 as highly expressed 
in early recurrence, compared to late or null 
recurrence cancer in a cohort of 47 bladder cancer 
patients, suggesting a role for this protein in the 
time of recurrence. Bhagirath and colleagues 
(Bhagirath et al., 2012) reported elevated STMN1 
mRNA levels in muscle invasive tumors. In 
agreement, patients with high Stathmin 1 
expression under taxane therapy had decreased 
recurrence-free survival by univariate analysis 
(Wosnitzer et al., 2011). In a cohort of 58 urothelial 
carcinoma patients, multivariate analysis revealed 
that Stathmin 1 positivity was associated with high 
grade tumors, recurrence and negatively impacted 
survival (Lin et al., 2009). 
Colorectal cancer 
Note 
In a cohort of 149 patients with colorectal cancer, 
high Stathmin 1 levels were an independent 
predictor of worse overall survival (Zheng et al., 
2010). In addition, Stathmin 1 expression was 
associated with tumor differentiation, invasion and 
stage of the disease (Zheng et al., 2010). In contrast, 
Ogino and colleagues (Ogino et al., 2009) showed 
that, by multivariate analysis, Stathmin 1 positivity 
had a protective effect on survival in a cohort of 
546 colorectal patients (stratified in obese and non-
obese individuals). Interestingly, obesity had a 
negative impact on survival in Stathmin 1 positive 
patients, but not in Stathmin 1-negative patients 
(Ogino et al., 2009). A recent study conduced by 
Tan and colleagues (Tan et al., 2012) corroborated 
the findings from Zheng and colleagues (Zheng et 
al., 2010), indicating that high Stathmin 1 levels 
negatively impacted survival in a cohort of 324 
colorectal cancer patients in univariate analysis. 
Tan and colleagues (Tan et al., 2012) also 
demonstrated functional evidences that Stathmin 1 
is a positive regulator of cell proliferation, 
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clonogenicity, migration and invasion in colorectal 
cancer cell lines. 
Gastric cancer 
Note 
Jeon and colleagues (Jeon et al., 2010) reported that 
a high expression of Stathmin 1 was an independent 
predictor of shorter recurrence-free survival, and 
associated with lymph node metastasis and high 
grade stages in a cohort of 226 gastric cancer 
patients. The authors, using two different gastric 
cancer cell lines (SNU638 and SNU16 cells), 
demonstrated that Stathmin 1 silencing decreased 
cell proliferation, migration, invasion and xenograft 
tumor growth (Jeon et al., 2010). Kang and 
colleagues (Kang et al., 2012), and Ke and 
colleagues (Ke et al., 2013), identified high 
Stathmin 1 expression in cell lines and primary 
cells from gastric cancer and predicted poor 
prognosis by univariate analysis. Interestingly, 
Kang and colleagues (Kang et al., 2012) also 
reported that Stathmin 1 silencing reduced the 
malignant phenotype in vitro and in vivo, and 
suggested that miR-223 is involved in the 
regulation of Stathmin 1 expression in gastric 
cancer cell lines (AGS and MKN7 cells). Another 
study, using lentivirus mediated RNAi delivery, 
also demonstrated that Stathmin 1 silencing reduced 
cell proliferation, migration and xenograft tumor 
growth in MKN-45 gastric cancer cells (Akhtar et 
al., 2013). 
Prostate cancer 
Note 
Using high-throughput immunoblotting, elevated 
Stathmin 1 expression was found in metastatic 
prostate cancer protein extracts (Varambally et al., 
2005). Another study reported that Stathmin 1 
expression was higher in advanced prostate tumors 
(Ghosh et al., 2007). Stathmin 1 silencing resulted 
in cell cycle arrest, reduced clonogenicity and 
increased apoptosis in prostate cancer cell line 
(LNCaP cells) (Mistry et al., 2005). In contrast, 
Stathmin 1 inhibition augmented the epithelial-to-
mesenchymal transition and metastasis potential in 
another prostate cancer cell line (DU145 cells) 
(Williams et al., 2012). 
Pheochromocytomas 
Note 
In a study conducted by Sadow and colleagues 
(Sadow et al., 2008), among the endocrine tumors, 
high levels of Stathmin 1 were observed in 
malignant pheochromocytomas. These results were 
confirmed by two other groups, who reported an 
overexpression of Stathmin 1 in 
malignant/metastatic pheochromocytomas 
compared to benign tumors or normal tissues 
(Björklund et al., 2010; Lin et al., 2011). 
Cervical cancer 
Note 
A higher Stathmin 1 expression was found in 
primary cells and cell lines from cervical carcinoma 
compared to normal cervical epithelial cells and 
also in tumor cells compared to matched adjacent 
non-carcinoma tissue (Xi et al., 2009). Increased 
Stathmin 1 expression correlated with a worse 
clinical stage and metastasis (Xi et al., 2009). 
Another study found Stathmin 1 overexpression in 
all cervical and rare expression of Stathmin 1 in 
benign samples; the authors suggest that the 
analysis of Stathmin 1 may be useful diagnostically 
in the identification of cervical cancer (Howitt et 
al., 2013). 
Glioma 
Note 
In a cohort of 24 glioma patients, increased 
Stathmin 1 levels were associated with decreased 
recurrence-free survival in univariate analysis (Ngo 
et al., 2007). Similar results were observed in a 
xenograft glioma nitrosourea-treated model (Ngo et 
al., 2007). Dong and colleagues (Dong et al., 2012) 
observed that Stathmin 1 expression was aberrantly 
expressed in vascular endothelial cells from glioma, 
especially in high grade cases and the Stathmin 1 
silencing reduced cell proliferation and invasion, 
and induced apoptosis in glioma-derived 
microvascular endothelial cells. 
Lung cancer 
Note 
Chen and colleagues (Chen et al., 2003) reported a 
high expression of Stathmin 1 in a cohort of 93 lung 
adenocarcinoma patients and this expression was 
associated with poorly differentiated tumors. 
Stathmin 1 overexpression was also found in 
primary non-small cell lung tumors matched with 
normal tissues (Singer et al., 2009). Rosell and 
colleagues (Rosell et al., 2003) observed that high 
Stathmin 1 levels negatively affected the time to 
progression in non-small-cell lung cancer patients, 
by univariate analysis. Of note, Stathmin 1 
inhibition decreased proliferation, migration and 
invasion in non-small cell lung cancer cell lines 
(Calu-1 and Calu-6 cells) (Singer et al., 2009). 
Medulloblastoma 
Note 
Using a microarray approach, Stathmin 1 was 
identified as differentially expressed in primary 
medulloblastoma samples and it was associated 
with unfavorable overall survival (Neben et al., 
2004). Accordingly, Kuo and colleagues (Kuo et 
al., 2009) reported that Stathmin 1 correlated with 
tumor dissemination and predicted decreased 
survival in medulloblastoma patients, by univariate 
analysis in both studies. 
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Pancreatic cancer 
Note 
Lu and colleagues (Lu et al., 2014) reported that 
Stathmin 1 was overexpressed in pancreatic cancer 
samples and that high Stathmin 1 levels were 
correlated with vascular emboli, tumor size, and 
negatively impacted overall survival in univariate 
analysis. In addition, Stathmin 1 silencing in 
pancreatic cancer cells resulted in reduced cell 
proliferation, clonogenicity and cell cycle arrest (Lu 
et al., 2014; Jiang et al., 2009). 
Thyroid cancer 
Note 
Using cDNA microarray approach, Onda and 
colleagues (Onda et al., 2004) reported that 
Stathmin 1 was overexpressed in all anaplastic 
thyroid cancer cell lines analyzed and this was 
confirmed by immunohistochemical analyses in 
primary samples. Another study also observed that 
Stathmin 1 was highly expressed in anaplastic 
thyroid carcinomas (Sadow et al., 2008). 
Cholangiocarcinoma 
Note 
In a cohort of 80 extrahepatic cholangiocarcinoma 
patients, high levels of Stathmin 1 correlated with 
invasion and shorter recurrence-free survival by 
multivariate analysis (Watanabe et al., 2014). The 
authors also demonstrated that Stathmin 1 silencing 
resulted in reduced cell proliferation capacity and 
increased sensitivity to paclitaxel treatment in a 
cholangiocarcinoma cell line (Watanabe et al., 
2014). 
Melanoma 
Note 
In primary melanoma samples, Stathmin 1 was 
highly expressed in two independent cohorts, but 
did not impacts survival (Chen et al., 2013a). 
Stathmin 1 silencing reduced cell proliferation and 
migration. Furthermore, Stathmin 1 overexpression 
potentiated both these cell processes in melanoma 
cell lines (Malme-3M and A375 cells) (Chen et al., 
2013a). 
Mesothelioma 
Note 
Overexpression of Stathmin 1 was found in all 
mesothelioma cell lines tested (LRK1A, H2052, 
211H, H290, MS1, H513 and H28 cells) and also in 
primary tumors compared to its matched normal 
tissue (Kim et al., 2007). 
Pediatric brain cancer 
Note 
Using 2-dimensional differential in-gel 
electrophoresis, immunohistochemistry and 
quantitative PCR, Stathmin 1 was identified as 
highly expressed in primary primitive 
neuroectodermal tumors compared to 
ependymomas samples (de Bont et al., 2007). 
Renal cancer 
Note 
In Wilms tumors, Stathmin 1 was highly expressed 
in high grade compared to low grade tumors 
(Takahashi et al., 2002). 
Sarcoma 
Note 
Belletti and colleagues (Belletti et al., 2008) 
reported that Stathmin 1 was increased in recurrent 
and metastatic sarcoma samples.  
In addition, overexpression of the wild type 
Stathmin 1 or mutated Stathmin 1 (Q18E, gain-of-
function mutation) potentiated the malignant 
phenotype in the sarcoma cell line HT1080 (Belletti 
et al., 2008). 
Salivary cancer 
Note 
Using 2-dimensional differential in-gel 
electrophoresis, increased Stathmin 1 expression 
was found in adenoid cystic carcinoma (Nakashima 
et al., 2006). 
To be noted 
Note 
Although Stathmin 1 regulates multiple important 
cellular functions, Schubart and colleagues 
(Schubart et al., 1996) initially reported that Stmn1 
knockout mice had normal growth, development, 
reproduction and did not show any aberrant 
phenotype. Later on, it was observed that Stmn1 
knockout mice developed an axonopathy of the 
central and peripheral nervous systems with aging 
(Liedtke et al., 2002). In addition, Shumyatsky and 
colleagues (Shumyatsky et al., 2005) reported that 
Stmn1 knockout mice had reduced memory in 
amygdala-dependent fear conditioning, failed to 
recognize danger environments (Shumyatsky et al., 
2005) and exhibited accelerated fear extinction 
(Martel et al., 2012). Using well-defined mouse 
models of carcinogenesis and Stmn1 knockout 
mice, D'Andrea and colleagues (D'Andrea et al., 
2012) demonstrated that Stmn1 did not impact on 
cancer onset. Regarding hematopoietic-related 
processes, Stmn1 knockout mice presented two 
human hematopoietic disease phenotypes: 
megaloblastic anemia and thrombocytosis 
(Ramlogan-Steel et al., 2012). Notably, Stmn1 
knockout mice did not have any that were 
alterations incompatible with life, and Stathmin 1 
inhibition in several types of cancer cells reduced 
the malignant phenotype, making it an attractive 
target for anticancer therapies. 
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